Raymond James analyst David Novak likes the quarterly results from BioSyent (BioSyent Stock Quote, ... Read More
If you’re looking for a pharma name with solid prospects you should be checking out Canadian compa... Read More
Another strong quarter has Cantor Fitzgerald Canada analyst Scott Curtis feeling bullish about BioSy... Read More
Cantor Fitzgerald Canada analyst Scott Curtis says that as the result of years of marketing and prom... Read More
BioSyent (TSXV:RX) today announced Q2 results that are indicative of the revenue and earnings moment... Read More
It was around 1999, and I was a pharmaceutical sales rep with Fournier Pharma, when I bumped into my... Read More
September has always had that “back to school” feeling in the capital markets as, for be... Read More
Share
Tweet
pin
Share